Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/AUROPHARMA stock hub

NSE/AUROPHARMA has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/AUROPHARMAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

863.8B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/AUROPHARMA

In the news

Latest news · NSE/AUROPHARMA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E20.4

P25 24.9P50 32.4P75 45.7

Trailing P/E24.8

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC10.3

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/AUROPHARMA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

201

Groups with data

Currency

INR

Showing 201 of 201 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	27,707
Employees Change	1,692%
Employees Change Percent	6.5
Enterprise value	INR 852.8B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE406A01037
Last refreshed	2026-05-10
Market cap	INR 863.8B
Price	INR 1,488
Price currency	INR
Rev Per Employee	11,975,984.41x
Sector	Healthcare
Sic	2834
Symbol	nse/AUROPHARMA
Website	https://www.aurobindo.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.04%
EV Earnings	24.46x
EV/EBIT	16.56x
EV/EBITDA	12.67x
EV/Sales	2.57x
Forward P/E	20.42x
P/B ratio	2.47x
P/E ratio	24.77x
P/S ratio	2.6x
PE Ratio10 Y	16.68x
PE Ratio3 Y	20.52x
PE Ratio5 Y	17.2x
PEG ratio	1.59x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	15.61%
EBITDA Margin	20.15%
Gross margin	57.97%
Gross Profit	INR 192.4B
Gross Profit Growth	7.59%
Gross Profit Growth Q	10.76%
Gross Profit Growth3 Y	13.97%
Gross Profit Growth5 Y	5.61%
Net Income	INR 34.9B
Net Income Growth	-0.12%
Net Income Growth Q	7.62%
Net Income Growth Quarters	2%
Net Income Growth Years	2%
Net Income Growth3 Y	20.4%
Net Income Growth5 Y	-8.32%
Pretax Margin	15.54%
Profit Margin	10.51%
Profit Per Employee	INR 1.3M
Profitable Years	13
Roa5y	6.46
Roe5y	13.75
ROIC	10.32
Roic5y	11.43

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	6.96%
Cagr15y	21.18%
Cagr1y	24.76%
Cagr20y	17.3%
Cagr3y	35.78%
Cagr5y	8.63%
Div CAGR10	4.81%
Div CAGR3	-12.64%
Div CAGR5	-1.21%
EPS Growth	0.38
EPS Growth Q	7.62
EPS Growth Quarters	2
EPS Growth Years	2
EPS Growth3 Y	20.76
EPS Growth5 Y	-8.16
Revenue Growth	7.31x
Revenue Growth Q	8.37x
Revenue Growth Quarters	13x
Revenue Growth Years	3x
Revenue Growth3 Y	11.11x
Revenue Growth5 Y	5.88x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 88.9B
Debt	INR 77.9B
Debt EBITDA	INR 1.15
Debt Equity	INR 0.22
Equity	INR 350.3B
Interest Coverage	13.49
Net Cash	INR 11B
Net Cash By Market Cap	INR 1.27
Net Debt EBITDA	INR -0.16
Net Debt Equity	INR -0.03
Tangible Book Value	INR 305.8B
Tangible Book Value Per Share	INR 527
WACC	4.33

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.5%
Dividend Growth	0%
Dividend Growth Years	1%
Dividend per share	INR 8
Dividend Years	25
Dividend Yield	0.54%
Last Dividend	INR 4

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	95.98%
1Y total return	24.74%
200-day SMA	1,185.3
3Y total return	150.38%
50-day SMA	1,321.3
50-day SMA vs 200-day SMA	50over200
5Y total return	51.26%
All Time High	1,592
All Time High Change	-6.55%
All Time High Date	2024-09-13
All Time Low	10.13
All Time Low Change	14,593.33%
All Time Low Date	2008-11-06
ATR	38.14
Beta	0.03
Beta1y	0.27
Beta2y	0.44
Ch YTD	25.76
High	1,513.4
High52	1,513.4
High52 Date	2026-05-08
High52ch	-1.47%
Low	1,480.1
Low52	1,016.1
Low52 Date	2025-09-01
Low52ch	46.41%
Ma50ch	12.6%
Price vs 200-day SMA	25.52%
RSI	70.73
RSI Monthly	66.54
RSI Weekly	75.92
Sharpe ratio	0.78x
Sortino ratio	1.4
Total Return	1.04%
Tr YTD	25.76
Tr15y	1,685.46%
Tr1m	11.86%
Tr1w	8.12%
Tr3m	24.91%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 51.8B
Operating Income Growth	3.35
Operating Income Growth Q	8.21
Operating Income Growth3 Y	25.44
Operating Income Growth5 Y	3.21
Operating margin	15.61

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	278,949,706%
Shares Insiders	15.22%
Shares Institutions	39.16%
Shares Out	580,801,623
Shares Qo Q	0.03%
Shares Yo Y	-0.5%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	1,367,359.45x
Bv Per Share	603.4
Ch10y	86.01
Ch15y	1,531.7
Ch1m	11.86
Ch1w	8.12
Ch1y	24.28
Ch20y	2,016.7
Ch3m	24.91
Ch3y	148.3
Ch5y	46.85
Ch6m	32.38
Change	0.61%
Change From Open	0.18
Close	1,478.7
Days Gap	0.43
Depreciation Amortization	15,066,775,000
Dollar Volume	1,514,288,174.4
Earnings Date	2026-05-30
EBIT	INR 51.8B
EBITDA	INR 66.9B
EPS	INR 60.04
F Score	2
Fiscal Year End	March
Founded	1,986
Graham Number	902.83086
Graham Upside	-39.31
Income Tax	INR 16.7B
Is Primary Listing	1
Last Earnings Date	2026-02-09
Last Report Date	2025-12-31
Last Split Date	2015-07-20
Last Split Type	Forward
Lynch Fair Value	INR 300
Lynch Upside	-79.82
Ma150	1,218.6
Ma150ch	22.08%
Ma20	1,404.3
Ma20ch	5.94%
Next Earnings Date	2026-05-30
Open	1,485
Payment Date	2025-08-21
Position In Range	22.82
Price Date	2026-05-08
Price EBITDA	INR 12.92
Ptbv Ratio	2.82
Relative Volume	0.77x
Revenue	331,818,600,000x
Tax By Revenue	5.04x
Tax Rate	32.41%
Tr20y	2,333.1%
Tr6m	32.38%
Volume	1,017,872

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/AUROPHARMA dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.5%

$8.00 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

-1.2%

1 consecutive years of growth

Total shareholder yield

+1.0%

Dividend yield + buyback yield combined

Performance

NSE/AUROPHARMA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/AUROPHARMA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+39.2%

Share of float held by funds and institutions

Insider ownership

+15.2%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.5%

Negative means the company is buying back shares.

Technical

NSE/AUROPHARMA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

70.7

Above 70: short-term overbought

Price vs 200-day MA

+25.5%

50/200-day relationship not available

Beta (5Y)

0.03

Less volatile than the market

Sharpe ratio

0.78

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/AUROPHARMA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/AUROPHARMA stock rating?

nse/AUROPHARMA is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/AUROPHARMA analysis?

The full report lives at /stocks/nse/AUROPHARMA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/AUROPHARMA?

The latest report frames nse/AUROPHARMA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/AUROPHARMA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.